1: Kurtz MB, Abruzzo G, Flattery A, Bartizal K, Marrinan JA, Li W, Milligan J, Nollstadt K, Douglas CM. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun. 1996 Aug;64(8):3244-51. PubMed PMID: 8757860; PubMed Central PMCID: PMC174214.
2: Aoki M, Andoh T, Ueki T, Masuyoshi S, Sugawara K, Oki T. BU-4794F, a new beta-1,3-glucan synthase inhibitor. J Antibiot (Tokyo). 1993 Jun;46(6):952-60. PubMed PMID: 8344877.
3: Bartizal K, Abruzzo G, Trainor C, Krupa D, Nollstadt K, Schmatz D, Schwartz R, Hammond M, Balkovec J, Vanmiddlesworth F. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother. 1992 Aug;36(8):1648-57. PubMed PMID: 1416847; PubMed Central PMCID: PMC192025.
4: VanMiddlesworth F, Omstead MN, Schmatz D, Bartizal K, Fromtling R, Bills G, Nollstadt K, Honeycutt S, Zweerink M, Garrity G, et al. L-687,781, a new member of the papulacandin family of beta-1,3-D-glucan synthesis inhibitors. I. Fermentation, isolation, and biological activity. J Antibiot (Tokyo). 1991 Jan;44(1):45-51. PubMed PMID: 2001985.
5: Schmatz DM, Romancheck MA, Pittarelli LA, Schwartz RE, Fromtling RA, Nollstadt KH, Vanmiddlesworth FL, Wilson KE, Turner MJ. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950-4. PubMed PMID: 2198575; PubMed Central PMCID: PMC54447.